TY  - GEN
AU  - Soria,J-C
AU  - DeBraud,F
AU  - Bahleda,R
AU  - Adamo,B
AU  - Andre,F
AU  - Dientsmann,R
AU  - Delmonte,A
AU  - Cereda,R
AU  - Isaacson,J
AU  - Litten,J
AU  - Allen,A
AU  - Dubois,F
AU  - Saba,C
AU  - Robert,R
AU  - D'Incalci,M
AU  - Zucchetti,M
AU  - Camboni,M G
AU  - Tabernero,J
TI  - Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
SN  - 1569-8041
PY  - 2015///0703
KW  - Adult
KW  - Aged
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - pathology
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Naphthalenes
KW  - analysis
KW  - Neoplasms
KW  - classification
KW  - Neovascularization, Pathologic
KW  - drug therapy
KW  - Protein Kinase Inhibitors
KW  - administration & dosage
KW  - Quinolines
KW  - Receptor, Fibroblast Growth Factor, Type 1
KW  - antagonists & inhibitors
KW  - Receptor, Fibroblast Growth Factor, Type 2
KW  - Receptors, Platelet-Derived Growth Factor
KW  - Vascular Endothelial Growth Factor Receptor-1
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
UR  - https://doi.org/10.1093/annonc/mdu390
ER  -